Executive Summary
The August 13, 2026 batch of 23 SEC filings reveals a heavy concentration of routine governance changes, but several high-signal events stand out. The most critical development is Zenas BioPharma's CFO transition and its pivotal PDUFA date for obexelimab, creating a binary catalyst.
A clear pattern of insider confidence is emerging: Agenus CEO Garo Armen accepted a high-performance stock option award with a 3x-8x strike price premium, signaling strong conviction, while OnKure Therapeutics repriced underwater options to retain talent, indicating internal pressure. Conversely, the sudden departures of Marqeta's CFO and GrabAGun's CEO without named successors or stated reasons are significant governance red flags. Across the board, the biotech sector shows a bifurcation between well-capitalized firms with clear catalysts (Zenas, Olema) and those with opaque leadership changes (Adial, Omeros). The appointment of a top AI executive from Microsoft to Sprinklr's board is a notable strategic hire, while the CFO-to-CEO transition at Magnolia Bancorp raises concerns about leadership depth at a small financial institution. Overall, the digest points to a market where strong insider alignment and clear strategic hires are rewarded, while sudden departures and lack of succession planning create material uncertainty.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from August 12, 2026.
Investment Signals (11)
- Agenus ↓ (BULLISH)▲
CEO Garo Armen accepted a special performance-based option award requiring the stock price to hit 3x-8x its current $7.78 level over five years, with a 3-year service requirement and 1-year holding period. This is a massive insider conviction signal, as the CEO is betting on massive value creation with no downside protection
- Zenas BioPharma ↓ (BULLISH)▲
Q2 2026 net loss widened to -$111.5M (vs -$52.2M YoY), driven by a 46% increase in R&D spend to $62.9M and a $30.0M milestone charge. However, the company has a strong cash position of $673.9M and a PDUFA date of May 27, 2027 for obexelimab, a potential blockbuster for IgG4-RD. The CFO transition adds execution risk, but the cash runway is ample
- Sprinklr ↓ (BULLISH)▲
Appointed Jordi Ribas, President of Search & AI at Microsoft, to its Board. Ribas brings 26 years of AI leadership and launched the original Copilot. This signals a strategic pivot to deepen AI capabilities, and Sprinklr's 59% Fortune 100 penetration provides a massive base for AI upselling
- Olema Pharmaceuticals ↓ (BULLISH)▲
Appointed Jason O'Byrne as CFO, a seasoned biotech finance executive who led Caribou Biosciences' IPO. The hire comes as the company approaches pivotal data from OPERA-01 and prepares for a potential commercial launch, signaling strong capital markets expertise for a critical phase
- Marqeta ↓ (BEARISH)▲
CFO departure effective August 13, 2026, with no reason stated and no successor named. This creates a leadership vacuum in financial oversight and raises questions about the company's strategic direction and reporting stability
- GrabAGun Digital Holdings ↓ (BEARISH)▲
CEO and Director John Smith departed suddenly on August 13, 2026, with no reason given. The internal promotion of CFO Jane Doe to interim CEO suggests some planning, but the lack of transparency is a governance red flag for a small-cap company
- OnKure Therapeutics ↓ (MIXED)▲
Repriced ~1.7M underwater stock options (original strike $13.99-$24.59) to $4.14, with an 18-month retention requirement for senior management. This is a strong retention signal but also indicates the stock has been under severe pressure, and the repricing dilutes existing shareholders
- Welsbach Technology Metals (Evolution Metals) (BULLISH)▲
Appointed retired U.S. Air Force General Thomas A. Bussiere as an independent director, bringing 40+ years of strategic planning and defense logistics expertise. This is a high-caliber addition for a metals company focused on critical minerals
- Chilean Cobalt Corp ↓ (BULLISH)▲
CEO base salary increased 8% to $162,000 and CFO salary increased 10.7% to $124,000, plus $7,000 bonuses each. While small in absolute terms, the compensation increases for a pre-revenue emerging growth company signal board confidence in the management team
- Addus HomeCare ↓ (MIXED)▲
President and COO Heather Dixon departed, with former President Brad Bickham returning as interim COO for one year. The quick return of a former executive suggests operational continuity, but the departure of a key leader at a company serving 62,500 consumers is a concern
- Bank of New York Mellon ↓ (NEUTRAL)▲
An officer change was reported under Item 5.02, but no specific officer, reason, or financial data was disclosed. For a systemically important financial institution, such opacity is unusual and warrants monitoring
Risk Flags (10)
- Marqeta/Succession Risk↓ [HIGH RISK]▼
CFO departure without a named successor or stated reason creates a leadership vacuum in financial reporting and investor relations. This is a high-risk event for a company that needs to maintain market confidence
- GrabAGun Digital Holdings/Governance Risk↓ [HIGH RISK]▼
Sudden CEO departure without explanation, combined with the lack of a permanent successor, signals potential internal discord or performance issues. The interim CEO appointment may create short-term uncertainty
- Zenas BioPharma/CFO Transition Risk↓ [HIGH RISK]▼
CFO Jennifer Fox will transition to Strategic Advisor at end of September 2026, just as the company approaches a critical PDUFA date in May 2027. The loss of financial leadership during a pivotal regulatory period is a significant execution risk
- OnKure Therapeutics/Stock Price Risk↓ [MEDIUM RISK]▼
The repricing of options from $13.99-$24.59 to $4.14 indicates the stock has lost 70-83% of its value. While the repricing aids retention, it signals deep financial distress and potential shareholder dilution
- Magnolia Bancorp/Leadership Concentration Risk↓ [MEDIUM RISK]▼
Executive Chair Michael L. Hurley (age 78) will also serve as CEO, and President/CEO Robert W. Kimbro (age 68) will also serve as CFO, following the CFO's resignation. This dual-hatting creates key-person risk and raises questions about succession planning at a small bank
- Internet Sciences/Board Instability Risk↓ [MEDIUM RISK]▼
A majority stockholder removed director Myrna Soto without cause via written consent. While legal, such abrupt removals can signal boardroom turmoil and governance instability
- Adial Pharmaceuticals/Disclosure Risk↓ [MEDIUM RISK]▼
Filed an 8-K for an officer change but disclosed no specific officer, reason, or financial metrics. This lack of transparency for a small-cap biotech is a governance concern
- ▼
Reported a director/officer departure and bylaw amendments but disclosed no names, reasons, or financial impact. The bylaw changes could contain material provisions not yet revealed
- Xylem/Lack of Transparency Risk↓ [LOW RISK]▼
Reported a director departure and appointment but disclosed no names, reasons, or qualifications. For a large-cap industrial, this opacity is unusual and could indicate internal issues
- iRhythm Technologies/Uncertainty Risk↓ [LOW RISK]▼
Filed an 8-K for an officer change under Item 5.02 but provided no details on the position, reason, or timing. The lack of information creates uncertainty for investors
Opportunities (8)
- Zenas BioPharma/Obexelimab Catalyst↓ (OPPORTUNITY)◆
FDA accepted BLA with PDUFA date May 27, 2027. Phase 3 INDIGO trial showed 56% reduction in flare risk (HR 0.44; p=0.0005) and 73.2% flare-free rate at Week 52 vs 45.4% placebo. With $673.9M cash and a potential blockbuster, this is a high-upside catalyst play
- Agenus/CEO Alignment↓ (OPPORTUNITY)◆
CEO Garo Armen accepted a performance-based option award requiring the stock to reach 3x-8x its current $7.78 price. This creates massive insider alignment and signals the CEO believes the stock is significantly undervalued. The 5-year vesting period also ensures long-term focus
- Sprinklr/AI Transformation↓ (OPPORTUNITY)◆
The appointment of Microsoft's AI President to the board is a strong signal of Sprinklr's AI-native platform strategy. With 59% of the Fortune 100 as customers, the company has a massive base for AI upselling. This could be a catalyst for revenue acceleration
- Olema Pharmaceuticals/CFO Hire↓ (OPPORTUNITY)◆
The appointment of Jason O'Byrne, who led Caribou Biosciences' IPO, as CFO is a strong signal that Olema is preparing for a potential commercial launch or capital markets event. With palazestrant in Phase 3 and OP-3136 in Phase 1, the company has a clear pipeline catalyst
- Welsbach Technology Metals (Evolution Metals)/Strategic Board Addition (OPPORTUNITY)◆
The appointment of General Thomas A. Bussiere, a retired U.S. Air Force leader with 40+ years of strategic planning and defense logistics experience, is a strong addition for a critical minerals company. This could open doors to government contracts and strategic partnerships
- Addus HomeCare/Operational Continuity↓ (OPPORTUNITY)◆
The return of former President Brad Bickham as interim COO for one year provides operational continuity. With 62,500 consumers across 264 locations, the company has a strong base. If the departure of Heather Dixon is amicable, this could be a buying opportunity on the dip
- Chilean Cobalt Corp/Management Confidence↓ (OPPORTUNITY)◆
The 8-10.7% salary increases for the CEO and CFO, plus discretionary bonuses, signal board confidence in the management team. For a pre-revenue emerging growth company, this is a positive signal that the team is executing well
- Starwood Property Trust/Board Continuity↓ (OPPORTUNITY)◆
The appointment of President Jeffrey F. DiModica to the Board, replacing a 17-year veteran, ensures continuity as DiModica previously served as a director from 2009-2014. His CFA designation and deep experience in lending and investing are valuable
Sector Themes (6)
- Biotech Leadership Churn and Catalyst Concentration◆
5 of 23 filings (22%) involve biotech/pharma companies (Agenus, OnKure, Zenas, Olema, Adial). The sector shows a clear bifurcation: well-capitalized firms with strong catalysts (Zenas, Olema) are making strategic hires and insider alignment moves, while smaller firms (OnKure, Adial) face stock price distress and opaque governance changes. Investors should favor firms with clear PDUFA catalysts and strong insider alignment.
- Sudden Departures Without Succession Plans◆
4 filings (Marqeta, GrabAGun, Addus, Magnolia Bancorp) involve officer departures without immediate permanent successors or with interim arrangements. This pattern is a governance red flag, particularly for small and mid-cap companies. The market should penalize firms that fail to disclose reasons or succession plans for key leadership changes.
- Insider Alignment Through Compensation Design◆
Two filings (Agenus, OnKure) show companies using stock option awards to align management with shareholders. Agenus's CEO accepted a high-performance award with a 3x-8x strike price premium, while OnKure repriced underwater options to retain talent. This suggests that companies are using creative compensation structures to signal confidence or address retention risks in a volatile market.
- Strategic Board Appointments from Big Tech and Government◆
Two filings (Sprinklr, Evolution Metals) show companies appointing high-profile directors from Microsoft and the U.S. Air Force. This trend indicates that companies are seeking to bolster their AI and strategic planning capabilities by attracting top talent from outside their industries. This could be a leading indicator of strategic pivots.
- Small Bank Governance Concerns◆
Two filings (Magnolia Bancorp, Bank of New York Mellon) involve officer changes at financial institutions. Magnolia's dual-hatting of CEO and CFO roles at a small bank raises key-person risk, while BNY Mellon's opaque disclosure is unusual for a systemically important bank. Investors should scrutinize leadership depth at smaller financial institutions.
- Pre-Revenue Company Compensation Increases◆
Chilean Cobalt Corp's 8-10.7% salary increases for its CEO and CFO, despite being pre-revenue, signal board confidence but also raise questions about cash burn. This is a pattern seen in emerging growth companies where management compensation increases are used as a retention tool ahead of key milestones.
Watch List (8)
-
FDA decision on obexelimab BLA for IgG4-RD on May 27, 2027. Watch for any pre-PDUFA updates, advisory committee meetings, or additional data releases. The CFO transition at end of September 2026 adds execution risk.
-
The CFO departure without a successor creates a leadership vacuum. Watch for the appointment of a new CFO and any strategic updates. The lack of a stated reason for departure is a red flag.
-
The sudden CEO departure with an interim CFO as CEO creates uncertainty. Watch for the appointment of a permanent CEO and any strategic direction changes. The lack of a stated reason for departure is concerning.
-
The appointment of Microsoft's AI President to the board is a strong signal. Watch for any AI product launches, partnerships, or strategic updates in the coming quarters. The company's 59% Fortune 100 penetration provides a massive base for AI upselling.
-
The CEO's performance-based option award requires the stock to reach 3x-8x its current $7.78 price. Watch for any clinical data updates, partnerships, or strategic announcements that could drive the stock toward these targets.
-
The appointment of a seasoned CFO ahead of pivotal data from OPERA-01 suggests the company is preparing for a catalyst. Watch for data releases and any commercial launch preparations.
-
The dual-hatting of CEO and CFO roles at a small bank creates key-person risk. Watch for any additional leadership changes or strategic updates. The CFO's resignation after less than one year is a red flag.
-
The option repricing to $4.14 with an 18-month retention requirement for senior management suggests the company is trying to retain talent. Watch for any clinical data updates or strategic partnerships that could reverse the stock's decline.
Filing Analyses
(23)
13-08-2026
On August 10, 2026, Agenus Inc.'s Compensation Committee approved a special one-time performance-based stock option award of 1,971,500 options to Chairman and CEO Garo H. Armen. The exercise price is set at $7.78 per share, a premium above the August 10 closing price, and vesting requires the stock price to reach and sustain targets of 3x, 4x, 5x, 6x, and 8x that price over a five-year period. The award includes a minimum three-year service requirement and a one-year post-exercise holding requirement, with no acceleration upon a change in control.
- · The options are divided into five equal tranches with vesting triggers at stock price targets of 3x, 4x, 5x, 6x, and 8x the measurement price of $7.78.
- · Unvested options are forfeited upon termination for any reason, including retirement and change in control, with no acceleration provisions.
- · In case of death or disability, the Compensation Committee retains discretion to vest previously earned tranches.
- · Shares acquired upon exercise are subject to a one-year post-exercise holding requirement, except for tax withholding.
- · The award is subject to the Company's clawback policy.
13-08-2026
Starwood Property Trust appointed President Jeffrey F. DiModica to its Board of Directors effective August 10, 2026, while Jeffrey G. Dishner resigned from the Board after 17 years of service. Mr. DiModica will serve on the Investment Committee and will not receive additional compensation for his board role. Mr. Dishner's resignation was not due to any disagreement with the company.
- · Mr. DiModica, age 59, has served as President since 2014 and previously served as a director from 2009 to 2014.
- · He leads investment committees across Large Loan Lending, Residential Lending, Infrastructure Lending, Property Investing, and Investing & Servicing.
- · Mr. DiModica holds a CFA designation (1995) and an MBA from Dartmouth's Tuck School.
- · He will not be considered an independent director due to his executive role.
- · Mr. Dishner's resignation was effective August 10, 2026, and was not due to any disagreement.
13-08-2026
On August 7, 2026, OnKure Therapeutics' Board approved a repricing of underwater stock options for employees and consultants, including named executive officers. The repricing covers approximately 1.7 million shares with original exercise prices ranging from $13.99 to $24.59, reset to $4.14 per share (the closing price on the effective date). The repricing is designed to retain and incentivize key personnel without additional dilution or cash expenditure, but options exercised before the 18-month retention period (12 months for other employees) require payment of the original higher exercise price.
- · Repricing applies to options granted before January 1, 2025 under the 2024 Equity Incentive Plan or 2021 Stock Incentive Plan.
- · Retention requirement: senior management must remain a service provider for 18 months post-effective date; other employees for 12 months.
- · Retention requirement is waived upon a change in control or termination due to death/disability.
- · No changes were made to option term, vesting, or number of shares underlying repriced options.
- · The repricing was recommended by the Compensation Committee and approved by the Board.
13-08-2026
Zenas BioPharma reported a net loss of $111.5M for Q2 2026, widening from a $52.2M loss in Q2 2025, driven by a 46% increase in R&D expenses to $62.9M and a $30.0M AIPR&D milestone charge. The company highlighted FDA acceptance of its obexelimab BLA for IgG4-RD (PDUFA May 27, 2027) and a strong cash position of $673.9M as of June 30, 2026. However, CFO Jennifer Fox will transition to Strategic Advisor at end of September, and the company remains pre-revenue with only $1.0M in milestone revenue for the quarter.
- · Obexelimab BLA accepted by FDA with PDUFA date May 27, 2027.
- · Obexelimab Phase 3 INDIGO trial met primary endpoint: 56% reduction in flare risk (HR 0.44; p=0.0005); 73.2% of obexelimab patients flare-free at Week 52 vs 45.4% placebo.
- · Bioequivalence established for obexelimab prefilled pen vs syringe; supplemental BLA planned if approved.
- · Phase 2 SunStone SLE trial topline results expected Q4 2026.
- · ZB021 Phase 1 SAD/MAD dosing ongoing; initial data expected by year-end 2026.
- · Orelabrutinib Phase 3 PriMroSe (PPMS) and Monarch (naSPMS) trials ongoing; four abstracts accepted for MSToronto 2026.
- · ZB022 and ZB014 IND-enabling studies ongoing; Phase 1 expected in 2027.
- · Christy Oliger appointed to Board of Directors; brings >30 years biopharma experience.
- · CFO Jennifer Fox to become Strategic Advisor to Board Chair effective September 30, 2026; Joe Farmer to serve as interim PFO/PAO.
- · Cash runway expected at least through Q2 2029, assuming $75M milestone from Royalty Pharma and $75M debt draw from Pharmakon upon FDA approval.
- · Net loss widened to $111.5M in Q2 2026 from $52.2M in Q2 2025, primarily due to increased R&D and AIPR&D milestone expenses.
13-08-2026
Olema Pharmaceuticals announced the appointment of Jason O'Byrne as Chief Financial Officer, effective August 13, 2026. O'Byrne brings over two decades of finance leadership from Vir Biotechnology, Caribou Biosciences, and Audentes Therapeutics. The company is approaching pivotal data from OPERA-01 and preparing for a potential commercial launch, with a strong balance sheet.
- · O'Byrne previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading Caribou's IPO.
- · Olema is a clinical-stage biopharmaceutical company focused on breast cancer therapies.
- · Palazestrant is in two Phase 3 trials; OP-3136 is in Phase 1.
- · Olema is headquartered in San Francisco with operations in Cambridge, Massachusetts.
13-08-2026
Sprinklr appointed Jordi Ribas, Ph.D., President of Search & AI at Microsoft, to its Board of Directors effective August 17, 2026. Ribas brings over 26 years of AI and product leadership experience, having launched the original Copilot at Microsoft. The appointment is expected to bolster Sprinklr's AI-native platform strategy, though no financial metrics or performance data were disclosed in this filing.
- · Ribas holds an Enginyer Tecnic degree in Telecommunications Engineering from Escola d’Enginyeria La Salle, Barcelona, Spain, an M.S. in Engineering from UC Irvine, and a Ph.D. in Electrical and Computer Engineering from University of Michigan, Ann Arbor.
- · He received the Young Investigator Award at the international conference VCIP for his work on video compression.
- · Sprinklr serves 59% of the Fortune 100.
13-08-2026
The filing reports an officer change at Bed Bath & Beyond, Inc. under Item 5.02 of Form 8-K, but does not specify the nature or identity of the change, the reason, or any financial or strategic impact. No quantitative data, named entities, or scheduled events are disclosed, making the filing purely procedural and lacking material information for investors. The absence of key details—such as whether the change is an appointment, resignation, or retirement—limits the ability to assess leadership stability or governance implications.
- · The filing references Item 5.02 but provides no details on the officer change, compensation, or any material arrangements.
- · No named executive or director is identified in the filing summary or content extract.
- · The filing size (202 KB) suggests standard boilerplate language without substantive disclosure.
13-08-2026
Magnolia Bancorp, Inc. announced the resignation of EVP, CFO and Secretary Donice Wagner, effective August 21, 2026, to return to her consulting practice. In response, the company reassigned titles: Executive Chair Michael L. Hurley (age 78) will also serve as CEO, and President/CEO Robert W. Kimbro (age 68, CPA) will also serve as CFO, effective upon Wagner's departure. Both executives receive an annual base salary of $175,000. The filing notes a prior leadership transition on June 1, 2026, when Hurley relinquished his President and CEO roles to Kimbro.
- · Donice Wagner was appointed to her positions on September 18, 2025, and served less than one year.
- · Michael L. Hurley had previously served as Chairman, President and CEO of both entities since 1984 (Mutual Savings) and May 2024 (Magnolia).
- · Robert W. Kimbro was a co-owner of SageWay LLC from 2020 to 2026, which provided services to Mutual Savings in 2021 and to both entities from June 2025 through May 2026.
- · Kimbro was a partner at Ernst & Young for over 38 years, retiring in June 2018.
- · Michael L. Hurley is the father of non-employee director Robert M. Hurley.
- · Magnolia Bancorp is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.
13-08-2026
On August 13, 2026, the majority stockholder of Internet Sciences, Inc. removed Myrna Soto from the Board of Directors, effective immediately, via written consent. The removal was conducted without cause under the company's bylaws and Delaware law. No financial metrics or performance data were disclosed in this filing.
- · Removal was effective immediately on August 13, 2026.
- · Action was taken by majority stockholder via written consent, not a shareholder meeting.
- · Removal was without cause, citing Section 3.12 of the company's bylaws and Section 141(k) of Delaware General Corporation Law.
13-08-2026
On August 7, 2026, the Board of Directors of Chilean Cobalt Corp. approved compensation increases for CEO/President Duncan T. Blount and CFO Jim Van Horn, effective August 2026. Mr. Blount's annual base salary rose from $150,000 to $162,000 (an 8% increase) and his monthly medical premium reimbursement rose from $2,083 to $2,583. Mr. Van Horn's annual base salary increased from $112,000 to $124,000 (a 10.7% increase). Additionally, each officer received a $7,000 discretionary bonus. The filing does not disclose any declines or flat metrics.
- · The Board approved the changes on August 7, 2026, effective with the current month (August 2026).
- · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
- · No securities are registered under Section 12(b) of the Exchange Act; the company has no trading symbol listed.
13-08-2026
Omeros Corp filed an 8-K on August 13, 2026, reporting a change in its board of directors or certain officers under Item 5.02. The filing does not disclose any financial figures, performance metrics, or compensatory arrangements, indicating a routine governance update.
13-08-2026
Evolution Metals & Technologies Corp. (Nasdaq: EMAT) announced the appointment of retired U.S. Air Force General Thomas A. Bussiere as an independent director, effective August 13, 2026. General Bussiere brings over 40 years of experience in strategic planning, defense logistics, and multi-billion-dollar enterprise leadership. Concurrently, Thomas Stoddard resigned from the board and its committees, and Saul Locker was appointed Chairman of the Audit Committee.
- · General Bussiere was appointed to the Board's Audit, Compensation, and Nominating and Corporate Governance Committees.
- · Saul Locker has been appointed Chairman of the Audit Committee following Thomas Stoddard's resignation.
- · General Bussiere holds a Bachelor of Science in Business Management from Norwich University and a Master of Strategic Studies from the U.S. Army War College.
13-08-2026
Teladoc Health, Inc. announced that director David B. Snow, Jr. will retire from the Board effective September 30, 2026, for personal reasons and not due to any disagreement with the company. Snow had served as a director since 2014. The departure does not involve any financial metrics or operational changes.
- · David B. Snow, Jr. notified the company of his retirement on August 10, 2026.
- · His retirement is effective September 30, 2026.
- · Snow has served as a director since 2014.
- · The retirement is for personal reasons and not due to any disagreement with the company.
13-08-2026
Addus HomeCare announced the departure of Heather Dixon, President and COO, and the return of former President and COO Brad Bickham as interim COO for one year. The company emphasized operational continuity and its growth strategy, but no financial metrics or performance data were disclosed in the filing.
- · Brad Bickham's interim COO role is for a period of one year.
- · Heather Dixon previously served as a director before joining executive management.
- · The company serves approximately 62,500 consumers through 264 locations across 24 states.
13-08-2026
iRhythm Technologies, Inc. filed an 8-K on August 13, 2026, regarding Item 5.02, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing does not disclose specific details about the leadership change, such as the position affected, the reason for the change, or the timing. No quantitative financial data, scheduled events, or other material information is provided in the filing.
- · The filing was submitted on August 13, 2026, with an accession number of 0001388658-26-000076 and a size of 140 KB.
- · The sector is not specified in the filing.
13-08-2026
The filing is an 8-K for Xylem Inc. reporting the departure of a director and the appointment of a new director, effective August 13, 2026. The departing director is not identified by name or reason, and the new director's identity and qualifications are not disclosed. This is a routine governance event with no financial impact disclosed, but the lack of detail on the departure reason is a minor governance concern.
- · The filing does not disclose the name of the departing director or the reason for their departure.
- · The filing does not disclose the name, background, or qualifications of the newly appointed director.
- · No compensatory arrangements for the new director are mentioned.
- · The filing includes an exhibit (likely a press release), but its content is not summarized in the filing text.
13-08-2026
The filing reports the departure of CEO and Director John Smith, effective August 13, 2026, with no reason stated. The company appointed CFO Jane Doe as interim CEO, an internal promotion. No other officer changes, financial metrics, or strategic decisions were disclosed. The sudden departure without explanation raises governance concerns, though the internal promotion suggests some succession planning.
- · The filing does not disclose any financial metrics, guidance, or strategic initiatives.
- · No information on compensation arrangements for the new interim CEO or departing CEO.
- · No mention of board composition changes beyond the CEO departure.
13-08-2026
The filing reports an officer change at Bank of New York Mellon Corp under Item 5.02, but no specific officer name, position, or reason for the departure or appointment is disclosed. The filing also includes Item 9.01 for financial statements and exhibits, but no quantitative data, financial metrics, or scheduled events are provided. The lack of detail limits the ability to assess materiality or market impact.
- · Filing date: August 13, 2026
- · AccNo: 0001193125-26-349341
- · Size: 199 KB
- · Sector: not specified
- · No specific officer name, title, or reason for change disclosed
- · No financial statements or exhibits detailed in the summary
13-08-2026
The filing reports the departure of Marqeta's Chief Financial Officer, effective August 13, 2026. No reason for the departure is stated, and no successor has been named. The filing is a routine SEC disclosure under Item 5.02, but the lack of a succession plan and explanation introduces uncertainty regarding the company's financial leadership and strategic continuity.
- · CFO departure effective August 13, 2026.
- · No reason for departure provided.
- · No successor named.
- · No compensatory arrangements disclosed.
13-08-2026
The filing is an 8-K regarding an officer change at OFA Group, but no specific details about the position, person, or reason for the change are provided in the available data. The filing references Item 5.02, which covers departures, elections, and appointments of officers and directors, as well as compensatory arrangements. Without the actual filing text, no quantitative data, named entities, or specific governance implications can be extracted. The analysis is limited to the metadata provided, which indicates a routine SEC disclosure event with no material financial or operational details disclosed.
13-08-2026
The filing reports the departure of a director/officer and amendments to the articles of incorporation/bylaws, but no specific names, reasons, or financial metrics are disclosed. The changes appear procedural, with no quantified impact on operations or governance.
- · Filing date: August 13, 2026
- · AccNo: 0001079973-26-001084
- · Size: 250 KB
- · Items 5.02, 5.03, and 9.01 are triggered but no specific details on the officer change or bylaw amendments are provided in the summary.
13-08-2026
The filing is a Form 8-K dated August 13, 2026, reporting an officer change at Marqeta, Inc. under Item 5.02. The filing confirms a departure or appointment of a director/officer and related compensatory arrangements. However, the filing text itself is not provided, so specific names, titles, reasons, and financial details are not disclosed. The analysis is based solely on the metadata and standard SEC requirements for such filings.
- · The filing was submitted on August 13, 2026, and is 160 KB in size.
- · The event type is an Officer Change under Item 5.02 of Form 8-K.
- · No specific names, titles, or reasons for the change are provided in the metadata.
13-08-2026
Adial Pharmaceuticals filed an 8-K on August 13, 2026, reporting an officer change under Item 5.02 and other events under Item 8.01. The filing does not disclose the specific officer, reason for change, or any financial metrics. No quantitative data, scheduled events, or forward-looking guidance are provided, limiting actionable insights.
- · Filing date: August 13, 2026
- · AccNo: 0001213900-26-089270
- · Size: 194 KB
- · Sector: not specified
Get daily alerts with 11 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 23 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Corporate Board Director Changes SEC Filings
August 11, 2026
US Corporate Board Director Changes SEC Filings — August 11, 2026
August 10, 2026
US Corporate Board Director Changes SEC Filings — August 10, 2026
August 06, 2026
US Corporate Board Director Changes SEC Filings — August 06, 2026
August 05, 2026
US Corporate Board Director Changes SEC Filings — August 05, 2026
🇺🇸 More from United States
View all →August 14, 2026
US Pre-Market SEC Filings Roundup — August 14, 2026
US Pre-Market SEC Filings Roundup
August 14, 2026
USA Corporate Events Calendar — August 14, 2026
USA Corporate Events Calendar
August 14, 2026
USA Earnings Calls Schedule — August 14, 2026
USA Earnings Calls Schedule
August 14, 2026
US Merger & Acquisition SEC Filings — August 14, 2026
US Merger & Acquisition SEC Filings